Compare SYSCO Corporation (SYY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs TG Therapeutics Inc — how do they compare? SYSCO Corporation trades at $81.58 (market cap $38.25B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: SYSCO Corporation is far larger — about 4.5× TG Therapeutics Inc's market cap, and SYSCO Corporation pays a 2.76% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SYY | TGTX | |
|---|---|---|
Market Cap | $38.25B | $8.53B |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $59.06 |
52-Week Low | $69.30 | $26.94 |
Enterprise Value | $51.43B | $8.74B |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sysco Corporation (SYY) trades at $79.84, down 0.26% with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported solid Q2 2026 earnings beat ($1.53 vs $1.51 expected) and maintains strong revenue growth, reaching $81.37B in 2025. Recent news highlights the company's $500M AI efficiency program and reaffirmed fiscal 2027 guidance, while analysts maintain a 60% buy rating with $88.25 consensus target.
Sysco presents a compelling investment case with attractive valuation (P/S 0.45), strong institutional interest, and AI-driven efficiency initiatives. However, risks include integration challenges from the Jetro Restaurant Depot acquisition, rising debt levels, and margin pressure from inflationary costs. The stock offers 10% upside to analyst targets but requires monitoring of execution on growth initiatives.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
